Third Quarter 2026
Filed Nov 5, 2026Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Clinical progress and a stated cash runway through the first half of 2029 were offset by lower revenue, higher research and development and general and administrative expenses, and a wider net loss for both the third quarter and nine-month period.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Contract research revenue, three months ended September 30, 2026GAAP | $300K | – | – |
| Licensing revenue, three months ended September 30, 2026GAAP | $1.18M | – | – |
| Total revenue, three months ended September 30, 2026GAAP | $1.48M | – | – |
| Cost of revenue, three months ended September 30, 2026GAAP | $189K | – | – |
| Research and development expense, three months ended September 30, 2026GAAP | $16.07M | – | – |
| General and administrative expense, three months ended September 30, 2026GAAP | $6.04M | – | – |
| Licensing expense, three months ended September 30, 2026GAAP | $1.13M | – | – |
| Revaluation of contingent consideration, three months ended September 30, 2026GAAP | −$600K | – | – |
| Total costs and expenses, three months ended September 30, 2026GAAP | $22.82M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$21.34M | – | – |
| Interest income, three months ended September 30, 2026GAAP | $1.85M | – | – |
| Non-cash royalty income, three months ended September 30, 2026GAAP | $985K | – | – |
| Total other income, three months ended September 30, 2026GAAP | $2.83M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$18.51M | – | – |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $ (0.12) | – | – |
| Weighted average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP | 149,449,067 | – | – |
| Total stock-based compensation expense, three months ended September 30, 2026GAAP | $3.02M | – | – |
| Contract research revenue, nine months ended September 30, 2026GAAP | $1.19M | – | – |
| Licensing revenue, nine months ended September 30, 2026GAAP | $3.91M | – | – |
| Total revenue, nine months ended September 30, 2026GAAP | $5.11M | – | – |
| Cost of revenue, nine months ended September 30, 2026GAAP | $802K | – | – |
| Research and development expense, nine months ended September 30, 2026GAAP | $49.79M | – | – |
| General and administrative expense, nine months ended September 30, 2026GAAP | $18.83M | – | – |
| Licensing expense, nine months ended September 30, 2026GAAP | $3.76M | – | – |
| Revaluation of contingent consideration, nine months ended September 30, 2026GAAP | −$300K | – | – |
| Total costs and expenses, nine months ended September 30, 2026GAAP | $72.88M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$67.77M | – | – |
| Interest income, nine months ended September 30, 2026GAAP | $5.12M | – | – |
| Non-cash royalty income, nine months ended September 30, 2026GAAP | $2.81M | – | – |
| Total other income, nine months ended September 30, 2026GAAP | $7.93M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$59.84M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $ (0.43) | – | – |
| Weighted average common shares outstanding, basic and diluted, nine months ended September 30, 2026GAAP | 140,407,589 | – | – |
| Total stock-based compensation expense, nine months ended September 30, 2026GAAP | $8.89M | – | – |
| Cash, cash equivalents and marketable securities, September 30, 2026GAAP | $204.6M | – | – |
| Total assets, September 30, 2026GAAP | $216.2M | – | – |
| Total current liabilities, September 30, 2026GAAP | $24.22M | – | – |
| Total liabilities, September 30, 2026GAAP | $49.36M | – | – |
| Total stockholders' equity, September 30, 2026GAAP | $166.8M | – | – |
| Common stock outstanding, September 30, 2026GAAP | 150,825,196 | – | – |
| Depreciation and amortization, nine months ended September 30, 2026GAAP | $309K | – | – |
| Changes in operating assets and liabilities, nine months ended September 30, 2026GAAP | −$11.13M | – | – |
| Net cash used in operating activities, nine months ended September 30, 2026GAAP | −$62.08M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Contract researchNot separately provided. | $300K | – | – |
| LicensingThe decrease in total revenue was primarily driven by a sales milestone achieved under the Sun Pharma license agreement during the quarter ended September 30, 2025. | $1.18M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Fourth Quarter 2026 and first half of 2029 outlook
- NoteReadout of top line results from the Phase 2 ADMIRATION trial of bosakitug in atopic dermatitis is expected in the fourth quarter 2026.
- NoteInitiation of the Phase 2b clinical trial of modzatinib in lichen planus is expected in the fourth quarter of 2026; first site activation is expected in November 2026.
- NoteFiling of an IND application for ATI-9494 is on track for fourth quarter 2026.
- NoteAclaris expects to start a Phase 2b trial of ATI-052 in eosinophilic esophagitis early next year.
- NoteCash, cash equivalents and marketable securities are expected to be sufficient to fund operations through the first half of 2029, without giving effect to potential business development transactions or additional financing activities.
What drove it
- ATI-052 Phase 1b proof-of-concept results in severe atopic dermatitis showed a 45% placebo-adjusted mean change in EASI score from baseline at week 8, a 78% placebo-adjusted EASI-50 at week 8, and a 43% placebo-adjusted mean improvement in itch at week 8.
- In asthma, a single dose of ATI-052 produced a 59% mean absolute reduction in FeNO (45 ppb) at day 15, a 40% reduction at day 29, and a placebo adjusted and absolute 200 ml improvement in FEV1 at day 15.
- Research and development expense increased primarily from ATI-052 manufacturing and Phase 1b clinical development in atopic dermatitis and asthma, plus ATI-9494 manufacturing and preclinical development expenses.
- General and administrative expense increased primarily due to professional and legal expenses and personnel and stock-based compensation expenses.
- The third-quarter and nine-month revenue decreases were primarily driven by a sales milestone achieved under the Sun Pharma license agreement during the corresponding 2025 periods.
Concerns
- Total revenue was $1.5 million for the third quarter of 2026 compared to $3.3 million for the third quarter of 2025.
- Net loss was $18.5 million for the third quarter of 2026 compared to $14.6 million for the third quarter of 2025.
- Net cash used in operating activities was $ (62,076) (unaudited, in thousands) for the nine months ended September 30, 2026, compared to $ (33,982) (unaudited, in thousands) for the nine months ended September 30, 2025.
- The October 2026 financing included the sale of 7.8 million shares and pre-funded warrants to purchase 6.5 million shares.
What to watch
- Top line results from the Phase 2 ADMIRATION trial of bosakitug in 109 patients with moderate-to-severe atopic dermatitis, expected in the fourth quarter 2026.
- First site activation and Phase 2b trial initiation for modzatinib in lichen planus, expected in November 2026 and the fourth quarter of 2026, respectively.
- IND filing for ATI-9494, on track for the fourth quarter 2026.
- Completion of the assessment of an additional Phase 2b indication for ATI-052, likely either atopic dermatitis or asthma, and the planned Phase 2b trial in eosinophilic esophagitis early next year.
- Execution against the stated cash runway through the first half of 2029.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $204.6 million as of September 30, 2026, compared to $151.4 million as of December 31, 2025.
- During October 2026, the Company sold 7.8 million shares of common stock and issued pre-funded warrants to purchase 6.5 million shares of common stock for aggregate gross proceeds of $50.0 million.
- Net cash used in operating activities was $ (62,076) (unaudited, in thousands) for the nine months ended September 30, 2026, compared to $ (33,982) (unaudited, in thousands) for the nine months ended September 30, 2025.
- Total liabilities were $ 49,358 (unaudited, in thousands) as of September 30, 2026, compared to $ 57,378 (unaudited, in thousands) as of December 31, 2025.
Analysis
Aclaris reported lower third-quarter revenue and a wider loss as it increased spending on its clinical pipeline. Total revenue was $1.5 million for the third quarter of 2026 compared to $3.3 million for the third quarter of 2025, with the company attributing the decrease primarily to a sales milestone under the Sun Pharma license agreement achieved in the 2025 period. Net loss was $18.5 million compared to $14.6 million, while net loss per share was unchanged at $ (0.12).
The expense profile reflects investment in ATI-052 and ATI-9494. Research and development expense was $16.1 million in the third quarter of 2026 compared to $13.0 million in the prior-year quarter, driven by ATI-052 manufacturing and Phase 1b development in atopic dermatitis and asthma, alongside ATI-9494 manufacturing and preclinical work. General and administrative expense was $6.0 million compared to $4.9 million, principally due to higher professional, legal, personnel and stock-based compensation expenses. A $0.6 million gain from contingent-consideration revaluation partly offset costs.
Clinical execution is the central reported positive. ATI-052 produced Phase 1b proof-of-concept results in severe atopic dermatitis and asthma, and the company intends to prioritize Phase 2b development initially in eosinophilic esophagitis. Near-term milestones include fourth-quarter 2026 top-line Phase 2 results for bosakitug in atopic dermatitis, Phase 2b initiation for modzatinib in lichen planus, and an ATI-9494 IND filing. These events are the principal upcoming evidence points for the pipeline.
Liquidity increased to $204.6 million as of September 30, 2026 from $151.4 million as of December 31, 2025. The company subsequently raised aggregate gross proceeds of $50.0 million in October 2026 through common-stock sales and pre-funded warrants. It stated that, including net proceeds from that offering, cash, cash equivalents and marketable securities should fund operations through the first half of 2029. However, nine-month operating cash use rose to $62.1 million from $34.0 million, making cash deployment and financing effects important alongside the clinical readouts.
Management, verbatim
Aclaris is developing unique product candidates designed to provide improved therapeutic options across a variety of inflammatory disorders with the goal of raising the efficacy ceiling, and our recent progress reflects continued execution toward that objective.
Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris
We recently announced strongly positive primary analysis results from our Phase 1b POC trials with ATI-052 in AD and asthma; we look forward to starting a Phase 2b trial in eosinophilic esophagitis early next year.
Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris
Not in the filing
stated, not guessed- Gross margin was not reported.
- Non-GAAP financial measures, including non-GAAP net income or loss and non-GAAP EPS, were not reported.
- Prior-quarter comparative figures and sequential changes were not reported.
- Free cash flow was not reported.
- Quarterly operating cash flow was not reported.
- Debt was not reported.
- Share repurchases and dividends were not reported.
- Numeric revenue, gross-margin, operating-expense and tax-rate guidance were not reported.
- Previous-release outlook was not provided, so comparison with prior guidance is unavailable.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.